One of the hottest issues in medtech reimbursement is whether there is a &nbsp;need for an expedited reimbursement program following the repeal of &nbsp;MCIT. In this episode of the Market Pathways podcast, former CMS &nbsp;Administrator and FDA Commissioner Mark McLellan weighs in on this and &nbsp;other reimbursement and regulatory concerns facing the device industry. &nbsp;
#medtech #MedicalDevices #FDA #CMS #MCIT
View the latest issue of Market Pathways: https://bit.ly/3M4gsLc
View more podcast episodes: https://bit.ly/3vgFTlT
About Market Pathways
Your premium guide to global medical device regulation, reimbursement &nbsp;&nbsp;and &nbsp;policy. Market Pathways delivers incomparable intelligence &nbsp;&nbsp;exploring the &nbsp;people, challenges, and opportunities impacting the &nbsp;&nbsp;global medtech &nbsp;regulatory and reimbursement community. View the latest &nbsp;&nbsp;issue of Market &nbsp;Pathways on MyStrategist.com

Sandra Siami on the Promise and Challenges of Real World Evidence

Your premium guide to global medical device regulation, reimbursement and policy. Market Pathways delivers incomparable intelligence exploring the people, challenges, and opportunities impacting the global medtech regulatory and reimbursement community. View the latest issue of Market Pathways on MyStrategist.com